Neuburgh Advisers LLC raised its stake in Masimo Co. (NASDAQ:MASI) by 78.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,280 shares of the medical equipment provider’s stock after buying an additional 3,200 shares during the period. Neuburgh Advisers LLC’s holdings in Masimo were worth $782,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of MASI. Ruggie Capital Group bought a new position in shares of Masimo in the 4th quarter worth $33,000. Quantamental Technologies LLC bought a new position in shares of Masimo in the 4th quarter worth $43,000. Financial Gravity Companies Inc. bought a new position in shares of Masimo in the 4th quarter worth $49,000. First Hawaiian Bank increased its holdings in shares of Masimo by 170.0% in the 4th quarter. First Hawaiian Bank now owns 1,080 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 680 shares during the last quarter. Finally, Bogart Wealth LLC increased its holdings in shares of Masimo by 13.7% in the 4th quarter. Bogart Wealth LLC now owns 1,161 shares of the medical equipment provider’s stock worth $124,000 after buying an additional 140 shares during the last quarter. 84.72% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on MASI shares. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Friday, November 16th. UBS Group started coverage on shares of Masimo in a report on Tuesday, November 27th. They issued a “buy” rating and a $137.00 price target on the stock. BidaskClub raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. Finally, Piper Jaffray Companies raised shares of Masimo from a “neutral” rating to an “overweight” rating and set a $120.00 price target on the stock in a report on Wednesday, December 19th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $132.00.
MASI stock opened at $133.37 on Friday. Masimo Co. has a 52 week low of $83.16 and a 52 week high of $135.75. The firm has a market cap of $7.08 billion, a P/E ratio of 44.02, a price-to-earnings-growth ratio of 2.74 and a beta of 1.18.
Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.10. Masimo had a net margin of 22.55% and a return on equity of 19.53%. The company had revenue of $223.10 million for the quarter, compared to analyst estimates of $220.96 million. During the same quarter last year, the firm earned $0.72 EPS. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, research analysts forecast that Masimo Co. will post 3.08 earnings per share for the current year.
In related news, insider Jon Coleman sold 2,000 shares of the stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $135.00, for a total transaction of $270,000.00. Following the transaction, the insider now owns 13,201 shares of the company’s stock, valued at approximately $1,782,135. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Anand Sampath sold 30,000 shares of the stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $115.00, for a total transaction of $3,450,000.00. Following the transaction, the chief operating officer now directly owns 42,518 shares in the company, valued at approximately $4,889,570. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,877 shares of company stock worth $5,464,010. 12.60% of the stock is owned by insiders.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.